Cargando…

Recombinant activated coagulation factor VII (rFVIIa) as an adjunctive hemostatic therapy in patients with multiple system organ failure and acute upper gastrointestinal bleeding

Detalles Bibliográficos
Autores principales:	Milanov, S, Milanov, M, Gyurov, E, Shterev, Z
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3301549/ http://dx.doi.org/10.1186/cc1993

Ejemplares similares

Efficacy of recombinant activated factor VII (rFVIIa; NovoSeven(®)) in obstetrical haemorrhagic shock
por: Sobieszczyk, S, et al.
Publicado: (2003)

Recombinant activated factor VII (rFVIIa-NovoSeven(®)-NovoNordisk) treatment of bleeding complications in intensive care unit
por: Bonadona, A, et al.
Publicado: (2002)

Use of 'Synercid'™ (Aventis) in 132 polytrauma patients with Gram-positive nosocomial infection
por: Gyurov, E, et al.
Publicado: (2003)

Relationship between intrapulmonary oxygen consumption and oxygenation index in patients with post-traumatic acute respiratory distress syndrome
por: Milanov, S, et al.
Publicado: (2003)

Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage
por: Aggarwal, Anita, et al.
Publicado: (2004)

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
por: Ng, Heng Joo, et al.
Publicado: (2006)

Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia
por: Poon, Man-Chiu
Publicado: (2007)

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
por: Nicosia, Dario, et al.
Publicado: (2019)

Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven(®)) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial
por: Thabut, D, et al.
Publicado: (2004)

Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury
por: Smith, Jason E, et al.
Publicado: (2019)

Nosocomial infection: main cause in development of septic complications in surgical postoperative patients
por: Gyurov, E, et al.
Publicado: (1999)

Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience
por: Shah, Nurfatin Mohd, et al.
Publicado: (2018)

Nosocomial infection: main cause in development of septic complications during postoperative period
por: Gyurov, E, et al.
Publicado: (2002)

Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use
por: Bomken, Charlotte, et al.
Publicado: (2009)

Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
por: Milošević, Danko, et al.
Publicado: (2014)

Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment
por: Montacir, Othman, et al.
Publicado: (2018)

Ketamine and midazolam mixture versus ketamine for analgesia/sedation in polytrauma patients with asthma
por: Gyurov, E, et al.
Publicado: (2004)

Intrapleural versus epidural analgesia with local anesthetics in patients with thoracic trauma
por: Gyurov, E, et al.
Publicado: (2004)

Regional variation of the off-licence use of rFVIIa for patients with uncontrolled haemorrhage in England
por: Spivey, MH, et al.
Publicado: (2010)

De-escalation therapy: 1-year experience in a general intensive care unit
por: Gyurov, E, et al.
Publicado: (2005)

Clinical pulmonary infection score (CPIS) dynamics in polytrauma patients with ventilator-associated pneumonia
por: Georgieva, M, et al.
Publicado: (2004)

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)
por: Rajpurkar, Madhvi, et al.
Publicado: (2019)

Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood
por: Haidl, Harald, et al.
Publicado: (2019)

Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury
por: Kim, Bobby, et al.
Publicado: (2014)

Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report
por: Ma, Hongbing, et al.
Publicado: (2021)

Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa)
por: Kyang, Lee S., et al.
Publicado: (2019)

Thromboelastometry as an Ancillary Tool for Evaluation of Coagulation Status after rFVIIa Therapy in a Pregnant Woman with Severe Hypoproconvertinemia—A Case Series and Review of the Literature
por: Krzyżanowski, Arkadiusz, et al.
Publicado: (2022)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Noninvasive positive pressure ventilation in patients with blunt chest trauma and acute respiratory failure
por: Milanov, S, et al.
Publicado: (2001)

Comparative analysis of two different total parenteral nutrition delivery systems
por: Milanov, S, et al.
Publicado: (2001)

Asymmetry in lung pathology and short-term effects of independent lung ventilation (ILV) on pulmonary mechanics and gas exchange in patients with blunt chest trauma
por: Milanov, S, et al.
Publicado: (2002)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

A randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of rFVIIa as adjunctive therapy for control of bleeding in patients with severe blunt trauma: a re-analysis following the exclusion of early (< 48 hours) deaths
por: Rossaint, R, et al.
Publicado: (2005)

Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
por: Heslet, Lars, et al.
Publicado: (2012)

No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis
por: An, Yang, et al.
Publicado: (2020)

Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding
por: Park, Jin-Seok, et al.
Publicado: (2019)

Treatment of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus Patient With Local Pulmonary Administration of Factor VIIa (rFVIIa): A Case Report
por: Alabed, Iehab B.
Publicado: (2014)

Hemostatic Powders in Non-Variceal Upper Gastrointestinal Bleeding: The Open Questions
por: Paoluzi, Omero Alessandro, et al.
Publicado: (2023)

The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
por: Altman, Raul, et al.
Publicado: (2010)

Topical hemostatic agents in the management of upper gastrointestinal bleeding: a meta-analysis
por: Alali, Ali A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_alsnufo09tvde8515pl2froniq